Alzamend Neuro (ALZN) News Today

$0.71
-0.02 (-2.74%)
(As of 04/24/2024 ET)
SourceHeadline
msn.com logoAlzamend Neuro And 2 Other Stocks Under $5 Insiders Are Buying
msn.com - April 24 at 9:21 AM
msn.com logoAlzamend Neuro (ALZN) Price Target Decreased by 16.00% to 21.42
msn.com - April 17 at 10:47 AM
msn.com logoALZN Stock Earnings: Alzamend Neuro Misses EPS for Q3 2024
msn.com - March 26 at 6:50 AM
msn.com logoAlzamend Neuro (ALZN) Price Target Increased by 25.00% to 25.50
msn.com - February 24 at 7:51 PM
realmoney.thestreet.com logoMaxim gets more bearish on Alzamend Neuro, downgrades shares
realmoney.thestreet.com - February 13 at 2:46 PM
msn.com logoAlzamend Neuro Risks Nasdaq Delisting Over Price Deficiency
msn.com - February 3 at 10:31 AM
markets.businessinsider.com logoBuy Rating for Alzamend Neuro Amid Promising Alzheimer’s Drug Trials and Market Potential
markets.businessinsider.com - December 19 at 6:51 PM
msn.com logoALZN Stock Earnings: Alzamend Neuro Beats EPS for Q1 2024
msn.com - December 18 at 12:33 PM
msn.com logoALZN Stock Earnings: Alzamend Neuro Reported Results for Q2 2024
msn.com - December 18 at 12:33 PM
finance.yahoo.com logoAlzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients
finance.yahoo.com - December 11 at 11:26 AM
finance.yahoo.com logoEXCLUSIVE: Alzamend Neuro Plans To Kickstart Stress Disorder Study With Next-Gen Lithium Product Next Year
finance.yahoo.com - December 11 at 11:26 AM
marketwatch.com logoAlzamend Neuro Gets FDA Approval for Trial of Depression Treatment
marketwatch.com - November 20 at 10:27 AM
msn.com logoEXCLUSIVE: Alzamend Neuro Receives FDA Go-Ahead Letter For Mid-Stage Major Depressive Disorder Study
msn.com - November 20 at 10:27 AM
finance.yahoo.com logoAlzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients
finance.yahoo.com - November 20 at 10:27 AM
finance.yahoo.com logoAlzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
finance.yahoo.com - November 16 at 10:02 AM
msn.com logoEXCLUSIVE: Alzamend Neuro Seeks FDA Approval For Mid-Stage PTSD Study With Next‑Gen Lithium Therapeutic Drug Candidate
msn.com - November 13 at 8:52 AM
finance.yahoo.com logoAlzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001
finance.yahoo.com - November 13 at 8:52 AM
msn.com logoAlzamend Neuro (ALZN) Price Target Increased by 1306.25% to 57.38
msn.com - November 2 at 12:25 AM
benzinga.com logoWhy Alzamend Neuro (ALZN) Stock Is Nosediving Today
benzinga.com - October 30 at 3:48 PM
finance.yahoo.com logoAlzamend Neuro Announces Reverse Stock Split
finance.yahoo.com - October 30 at 9:47 AM
finance.yahoo.com logoAlzamend Neuro, Inc. (9ZT0.F)
finance.yahoo.com - October 25 at 7:25 PM
businesswire.com logoAlzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001
businesswire.com - October 23 at 12:38 PM
msn.com logoEXCLUSIVE: Alzamend Neuro To Start Next-Gen Therapy Study For Bipolar Disorder
msn.com - October 2 at 8:54 AM
finance.yahoo.com logoAlzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients
finance.yahoo.com - October 2 at 8:54 AM
seekingalpha.com logoAlzamend Neuro CFO Katzoff buys 53K shares
seekingalpha.com - September 27 at 3:26 PM
yahoo.com logoRep. Jennifer Wexton Will Not Run for Re-Election After Rare Neurological Disorder Diagnosis
yahoo.com - September 26 at 6:09 PM
finance.yahoo.com logoAlzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement
finance.yahoo.com - September 22 at 12:54 PM
msn.com logoEXCLUSIVE: Alzamend Seeks FDA Approval For Study For Upgraded Version Of Most Commonly Used Treatment For Bipolar Disorder
msn.com - August 30 at 9:31 AM
finance.yahoo.com logoAlzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients
finance.yahoo.com - August 30 at 9:31 AM
benzinga.com logoBenzinga Neuro
benzinga.com - August 25 at 6:57 PM
finance.yahoo.com logoWe're A Little Worried About Alzamend Neuro's (NASDAQ:ALZN) Cash Burn Rate
finance.yahoo.com - August 24 at 4:32 PM
markets.businessinsider.com logoMaxim Group Reaffirms Their Buy Rating on Alzamend Neuro (ALZN)
markets.businessinsider.com - June 28 at 10:07 AM
morningstar.com logoAlzamend Neuro Inc Ordinary Shares
morningstar.com - June 24 at 10:33 AM
finance.yahoo.com logoAlzamend Neuro Announces Positive Phase IIA Clinical Trial Results for AL001
finance.yahoo.com - June 22 at 12:49 PM
benzinga.com logoEXCLUSIVE: Alzamend Neuro Identifies Potential AL001 Dose Level For Upcoming Alzheimer's Study
benzinga.com - June 22 at 7:49 AM
finance.yahoo.com logoAlzamend Neuro CEO Stephan Jackman to Participate on the "Mental Health, More Critical Than Ever" Panel at the Maxim Group’s Virtual Healthcare Conference
finance.yahoo.com - June 13 at 9:11 AM
benzinga.com logoAlzamend Neuro Stock (NASDAQ:ALZN), Dividends
benzinga.com - April 14 at 7:59 AM
msn.com logoMaxim Group Initiates Coverage of Alzamend Neuro (ALZN) with Buy Recommendation
msn.com - April 12 at 6:58 PM
finance.yahoo.com logoAlzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
finance.yahoo.com - April 3 at 9:56 AM
finance.yahoo.com logoEXCLUSIVE: Alzamend Neuro Starts Phase 1/2A Trial For Its Alzheimer's Immunotherapy Vaccine
finance.yahoo.com - April 3 at 9:56 AM
finance.yahoo.com logoKILL Alzamend Neuro Receives FDA "Study May Proceed" Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
finance.yahoo.com - April 3 at 9:56 AM
finance.yahoo.com logoEXCLUSIVE: Alzamend Neuro Completes Clinical Portion Of Mid-Stage Alzheimer's Trial
finance.yahoo.com - March 22 at 12:35 PM
finance.yahoo.com logoWe Think Alzamend Neuro (NASDAQ:ALZN) Needs To Drive Business Growth Carefully
finance.yahoo.com - March 17 at 8:29 AM
finance.yahoo.com logoAlzamend Neuro Reports Third Fiscal Quarter Financial Results and Provides a Business Update
finance.yahoo.com - March 16 at 9:44 AM
barrons.com logoAlzamend Neuro Inc.
barrons.com - February 21 at 12:23 AM
finance.yahoo.com logoAlzamend Neuro to Present at Sequire Biotechnology Conference
finance.yahoo.com - January 26 at 9:47 AM
finance.yahoo.com logoAlzamend Neuro Partners With Biorasi to Conduct a First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase I/IIA Clinical Trial
finance.yahoo.com - January 4 at 9:31 AM
finance.yahoo.com logoEXCLUSIVE: Alzamend Neuro Partners With Stem Cell Institute For Immunotherapy Vaccine Trial For Dementia
finance.yahoo.com - December 28 at 1:24 PM
finance.yahoo.com logoAlzamend Neuro Partners With the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami for ALZN002 Phase I/IIA Immunotherapy Vaccine Clinical Trial to Treat Mild to Moderate Dementia of the Alzheimer’s Type
finance.yahoo.com - December 28 at 8:23 AM
finance.yahoo.com logoIn a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc.
finance.yahoo.com - November 22 at 7:05 PM
Get Alzamend Neuro News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALZN and its competitors with MarketBeat's FREE daily newsletter.

He Is Giving Away Bitcoin (Ad)

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

>> Register right here

ALZN Media Mentions By Week

ALZN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ALZN
News Sentiment

0.50

0.43

Average
Medical
News Sentiment

ALZN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ALZN Articles
This Week

2

0

ALZN Articles
Average Week

Get Alzamend Neuro News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALZN and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:ALZN) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners